ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2025




ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2025

TEL AVIV, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including updated interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment of patients with low-grade UTUC, will be presented at the 26^th Annual Meeting of the Society of Urologic Oncology (SUO 2025) taking place December 2 – 5, 2025, in Phoenix, Arizona.

Poster & Session Details:

Poster Title: ENLIGHTED Phase 3 study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC)
Presenter: Vitaly Margulis, M.D., Professor of Urologic Oncology, University of Texas Southwestern
Medical Center
Poster Number: 166
Session Title: SUO Top Abstract Tour
Session Date & Time: December 4, 2025, 4:30 PM MST

In addition, the Company recently delivered an encore presentation of data from the Phase 3 ENLIGHTED trial at the 17^th European Multidisciplinary Congress on Urological Cancers (EMUC 2025) on November 15, 2025. The poster, titled “ENLIGHTED phase 3 study: Interim Results of Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic therapy (VTP) in the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC),” featured an interim analysis that had previously been presented at ASCO 2025, showing Padeliporfin VTP induced a complete response (CR) in 73% (27/37) of evaluable patients and maintained a safe and well-tolerated profile. The interim analysis captured results from 50% of target enrollment in ENLIGHTED as of the November 5, 2024 data cutoff.

About ImPact Biotech

ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: www.impactbiotech.com and the ENLIGHTED clinical trial website (for the US): https://www.enlighted-study.com.

Contacts

Global Head of Business Development
Guy Schmidt
guy.schmidt@impactbiotech.com

Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference




Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference

CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed, will be presenting at the 37th Annual Piper Sandler Healthcare conference on Wednesday, December 3rd at 9:00-9:25 am ET in New York, NY. During the conference, Carlsmed Management will be hosting 1×1 investor meetings.

A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://investors.carlsmed.com/.

About Carlsmed, Inc.

Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Investor Relations
Caroline Corner, PhD
IR@Carlsmed.com

Media
LeAnn Burton
Senior Director Brand Marketing
LBurton@Carlsmed.com

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)




BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on November 17, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 12 new employees in restricted stock units for an aggregate of 34,199 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com   
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

Patriot Mobile Named SoldierStrong’s 2025 Corporate Recipient of the Annual Commitment to Service Award




Patriot Mobile Named SoldierStrong’s 2025 Corporate Recipient of the Annual Commitment to Service Award

STAMFORD, Conn., Nov. 19, 2025 (GLOBE NEWSWIRE) — SoldierStrong, the national nonprofit committed to delivering revolutionary medical technologies to America’s veterans, is proud to announce Patriot Mobile as the 2025 Corporate Recipient of its Annual Commitment to Service Award.

The Commitment to Service Award recognizes companies and individuals who have demonstrated exemplary and inspirational leadership, and provided material support to SoldierStrong’s mission. Recipients leverage their talents and resources to help elevate the standard of excellence in health care available to our nation’s veterans.

Since 2013, Patriot Mobile has offered Americans a reliable alternative for cell phone service, delivering nationwide 4G and 5G coverage along with exceptional U.S.-based customer support. Patriot Mobile has long been a strong advocate for military, veterans, first responders, and their families by giving a portion of every dollar to support organizations that fight for our freedom.

“At Patriot Mobile, we believe that business should be a force for good, and Soldier Strong is an example how much good can be done when we unite purpose with passion,” said Glenn Story, Patriot Mobile’s Founder and CEO. “We are so passionate about taking care of our military, veterans and first responders, we made it one of our main pillars of giving. I accept this award as a call to continue serving our heroes with the same dedication they’ve shown serving America.”

SoldierStrong has been honored to join forces with Patriot Mobile over the past year in a shared dedication to supporting veterans and their families. Contributions from Patriot Mobile have helped support SoldierStrong’s efforts to donate wearable robotic exoskeletons, known as SoldierSuits, which are used to aid paralyzed veterans in walking again, as well as BraveMind virtual reality software and hardware systems used to treat post-traumatic stress in post-9/11 veterans. SoldierStrong has donated more than $7.3 million in revolutionary medical technologies since 2013, including 30 SoldierSuits and 31 BraveMind systems to date.

“SoldierStrong is proud to recognize Patriot Mobile for their steadfast commitment to our veterans and our mission, which has not only transformed the lives of countless individuals but has also set a shining example for all Americans to follow,” said Dr. Chris Meek, co-founder and chairman of SoldierStrong. “Through Patriot Mobile’s leadership, the company has uplifted veterans and ignited a flame of hope and resilience that inspires us all to strive for greater heights in our mission to support those who have sacrificed so much for our nation.”

Past corporate and individual recipients include WWE Inc., United Rentals Inc., S&P Global, Bobby Rahal Automotive Group, Flags of Valor, Martha MacCallum of FOX News, IndyCar driver Graham Rahal, former Congressman Jon Runyan, and Lieutenant General (Ret.) Patricia D. Horoho, the 43rd Surgeon General of the U.S. Army.

Patriot Mobile CEO Glenn Story accepted the award last night at an event hosted by the company to benefit SoldierStrong at the American Journey Experience in Irving, Texas.

About SoldierStrong

Since 2009, SoldierStrong has assisted America’s military veterans in taking their next steps forward in life after service. Our mission is fully realized through the donation of revolutionary medical technology to Veterans Affairs medical facilities and individual veterans across the country. These revolutionary medical technologies include the SoldierSuit, a wearable robotic exoskeleton used to help paralyzed and injured veterans walk again, and the BraveMind virtual reality system used to treat post-9/11 veterans living with the devastating impacts of post-traumatic stress (PTS). To date, SoldierStrong has donated more than $7.3 million in advanced medical technology, including 30 SoldierSuits and 31 BraveMind systems. For more information, visit soldierstrong.org.

About Patriot Mobile

Patriot Mobile is America’s ONLY Christian conservative wireless provider. Since 2013, Patriot Mobile has given Americans a conservative alternative for their cell service by providing dependable nationwide coverage on 4G and 5G networks and exceptional U.S.-based customer support. Patriot Mobile gives a portion of every dollar to support organizations that fight for our freedom. Patriot Mobile’s mission is to passionately defend our God-given rights and freedoms, and to glorify God always. For more information, visit www.patriotmobile.com.

Contact: Christina Stroback (SoldierStrong)
319.936.9300
christina@soldierstrong.org
Contact: Leigh Wambsganss (Patriot Mobile)
media@patriotmobile.com

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”




Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Company has pro forma cash of approximately $14 million following recent public offering

HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under the stock ticker “SLRX.”

S&P CapIQ inaccurately characterized the Salarius Pharmaceuticals and Decoy Therapeutics merger and inaccurately stated that the Company had been delisted from the Nasdaq Capital Market. The Company is working to have this inaccurate information corrected. Similar inaccuracies that appeared on Yahoo Finance were corrected earlier this week.

On November 13, 2025, Salarius completed an underwritten public offering raising gross proceeds of $8 million and consummated the previously announced merger with Decoy Therapeutics (Decoy). As of the date of this release, the combined company had pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. The company is focused on advancing Decoy’s pipeline of peptide conjugate therapeutics engineered through its IMP³ACT platform that reduces the complexity of drug development and manufacturing.

During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and to make progress on other programs including a novel broad-acting antiviral to treat flu, COVID-19 and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers.

About Salarius Pharmaceuticals
Salarius is focused on advancing Decoy’s pipeline of peptide conjugate therapeutics through its IMP³ACT platform, which uses artificial intelligence (AI), machine learning (ML) and high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the combined company, including without limitation, statements relating to plans and expectations relating to the business, scientific advisory board, products, including expected achievement of milestones for its lead asset and future prospects of the combined company. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of the combined company, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: risks related to the combined company’s ability to satisfy the initial listing standards in the required timeframe; risks that the combined company will not achieve the synergies expected from the proposed merger; risks that the combined company will not obtain sufficient financing to execute on their business plans; risks that Salarius will be unable to obtain stockholder approval for the conversion of the preferred stock; and risks related to the combined company’s products and development plans, including unanticipated issues with any IND application process and the potential of the IMP³ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by Salarius in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Salarius’ actual results may vary materially from those expected or projected.

CONTACT:

Alliance Advisors IR
Jody Cain
jcain@allianceadvisors.com
310-691-7100

IPSEN – Buy-back programme – Art 5 of MAR – Week 46 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 46 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 46_2025

IPSEN – Buy-back programme – Art 5 of MAR – Week 46 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 46 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 46_2025

Aeroflow Health Named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025




Aeroflow Health Named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025

Recognition Highlights Company’s Technology Platform That Expands Healthcare Access for Millions of Members Nationwide

ASHEVILLE, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) — Aeroflow Health, a healthcare company pioneering technology for medical products and services, has been named #12 on The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025 for its innovation, patient impact, and market influence.

The distinction spotlights Aeroflow Health’s secure technology, which enables patients to access essential medical supplies quickly. New mothers receive breast pumps before delivery; sleep apnea patients instantly confirm CPAP insurance coverage; and diabetes patients avoid supply gaps with automated, predictive refill reminders.

“Being named to this list validates what we’ve built: cutting-edge technology that handles millions of transactions annually while keeping member satisfaction above 98%. That balance between scale and humanity is what sets us apart,” said Casey Hite, CEO of Aeroflow Health. “Behind every algorithm and API we build is someone’s grandmother trying to manage her diabetes, someone’s husband finally getting treatment for sleep apnea, or a new mom navigating breastfeeding challenges. Our technology turns weeks into minutes and confusion into clarity.”

Aeroflow Health’s technology-enabled care model delivers measurable impact for patients and health plan partners, including:

• Instant Insurance Verification: Advanced API integrations provide coverage confirmation in seconds instead of waiting days or weeks, with proprietary technology eliminating traditional verification bottlenecks.
• Dramatic Time Savings: Technology-driven workflows reduce wait times from 30 days to just 3 hours for critical medical equipment, ensuring patients get supplies when they need them.
• Prevention of Care Gaps: Machine learning algorithms power automated refill reminders and proactive outreach, ensuring diabetic testing supplies arrive before patients run out, preventing emergency room visits.
• Universal Access Through Technology: Cloud-based platform ensures rural patients receive the same streamlined digital experience as those in major cities, removing geography as a barrier to quality care.
• Human-Centered Technology Support: Intelligent automation handles the paperwork so care teams can focus on what matters, creating simpler, more connected care experiences such as helping nervous CPAP users adjust to therapy or guiding new mothers through insurance benefits.

“Customers consistently tell us they appreciate how we’ve simplified access to care. We’re able to do that so seamlessly because of our powerful technology operating behind the scenes,” said Ryan Bullock, Chief Strategy Officer of Aeroflow Health. “When someone with diabetes can focus on their health instead of chasing down supplies, or when a new parent can get breastfeeding support without navigating insurance bureaucracy, that’s validation that our technology investments are creating real value for both members and our health plan partners.”

The company’s technology platform currently processes millions of transactions annually through its four specialized divisions: Aeroflow Breastpumps, Aeroflow Sleep, Aeroflow Diabetes, and Aeroflow Urology. Each transaction represents a family receiving support when they need it, a patient maintaining therapy adherence through seamless digital tools, or someone managing a chronic condition with one less barrier to care.

About Aeroflow Health

Aeroflow Health is a leading provider of durable medical equipment and health services, headquartered in Asheville, North Carolina. Committed to improving quality of life through innovative solutions, Aeroflow Health partners with healthcare providers and communities to offer comprehensive medical equipment and supplies, ensuring patients receive the care they need when they need it most. For more information, visit www.aeroflowhealth.com.

About The Healthcare Technology Report

The Healthcare Technology Report is a leading publication covering innovation, digital transformation, and technology adoption in healthcare. Its annual Top Healthcare Technology Companies list recognizes organizations demonstrating exceptional leadership in advancing technology-enabled care and improving patient outcomes. For more information, visit www.thehealthcaretechnologyreport.com.

Media Contact:
FischTank PR
aeroflow@fischtankpr.com

Aeroflow Health Named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025




Aeroflow Health Named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025

Recognition Highlights Company’s Technology Platform That Expands Healthcare Access for Millions of Members Nationwide

ASHEVILLE, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) — Aeroflow Health, a healthcare company pioneering technology for medical products and services, has been named #12 on The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025 for its innovation, patient impact, and market influence.

The distinction spotlights Aeroflow Health’s secure technology, which enables patients to access essential medical supplies quickly. New mothers receive breast pumps before delivery; sleep apnea patients instantly confirm CPAP insurance coverage; and diabetes patients avoid supply gaps with automated, predictive refill reminders.

“Being named to this list validates what we’ve built: cutting-edge technology that handles millions of transactions annually while keeping member satisfaction above 98%. That balance between scale and humanity is what sets us apart,” said Casey Hite, CEO of Aeroflow Health. “Behind every algorithm and API we build is someone’s grandmother trying to manage her diabetes, someone’s husband finally getting treatment for sleep apnea, or a new mom navigating breastfeeding challenges. Our technology turns weeks into minutes and confusion into clarity.”

Aeroflow Health’s technology-enabled care model delivers measurable impact for patients and health plan partners, including:

• Instant Insurance Verification: Advanced API integrations provide coverage confirmation in seconds instead of waiting days or weeks, with proprietary technology eliminating traditional verification bottlenecks.
• Dramatic Time Savings: Technology-driven workflows reduce wait times from 30 days to just 3 hours for critical medical equipment, ensuring patients get supplies when they need them.
• Prevention of Care Gaps: Machine learning algorithms power automated refill reminders and proactive outreach, ensuring diabetic testing supplies arrive before patients run out, preventing emergency room visits.
• Universal Access Through Technology: Cloud-based platform ensures rural patients receive the same streamlined digital experience as those in major cities, removing geography as a barrier to quality care.
• Human-Centered Technology Support: Intelligent automation handles the paperwork so care teams can focus on what matters, creating simpler, more connected care experiences such as helping nervous CPAP users adjust to therapy or guiding new mothers through insurance benefits.

“Customers consistently tell us they appreciate how we’ve simplified access to care. We’re able to do that so seamlessly because of our powerful technology operating behind the scenes,” said Ryan Bullock, Chief Strategy Officer of Aeroflow Health. “When someone with diabetes can focus on their health instead of chasing down supplies, or when a new parent can get breastfeeding support without navigating insurance bureaucracy, that’s validation that our technology investments are creating real value for both members and our health plan partners.”

The company’s technology platform currently processes millions of transactions annually through its four specialized divisions: Aeroflow Breastpumps, Aeroflow Sleep, Aeroflow Diabetes, and Aeroflow Urology. Each transaction represents a family receiving support when they need it, a patient maintaining therapy adherence through seamless digital tools, or someone managing a chronic condition with one less barrier to care.

About Aeroflow Health

Aeroflow Health is a leading provider of durable medical equipment and health services, headquartered in Asheville, North Carolina. Committed to improving quality of life through innovative solutions, Aeroflow Health partners with healthcare providers and communities to offer comprehensive medical equipment and supplies, ensuring patients receive the care they need when they need it most. For more information, visit www.aeroflowhealth.com.

About The Healthcare Technology Report

The Healthcare Technology Report is a leading publication covering innovation, digital transformation, and technology adoption in healthcare. Its annual Top Healthcare Technology Companies list recognizes organizations demonstrating exceptional leadership in advancing technology-enabled care and improving patient outcomes. For more information, visit www.thehealthcaretechnologyreport.com.

Media Contact:
FischTank PR
aeroflow@fischtankpr.com

SimpleTherapy Recognized as a Top 50 Healthcare Technology Company of 2025




SimpleTherapy Recognized as a Top 50 Healthcare Technology Company of 2025

FRESNO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) — SimpleTherapy, a leader in virtual musculoskeletal (MSK) and behavioral health care solutions, is honored to be named one of The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025. This marks the company’s second consecutive year on the list, following last year’s placement in the Top 100. The recognition highlights SimpleTherapy’s ongoing dedication to providing inclusive, holistic, and accessible care tailored to each individual.

“Our inclusion in this list reflects our ongoing commitment to supporting members on their health journey through technology that’s easy to access and simple to use,” said Jeremy Oswald, President of SimpleTherapy. “We’re proud to meet people where they are, whether on their phones, tablets, laptops, or in person, while delivering care that’s truly personal and effective.”

SimpleTherapy offers five solutions that touch on an individual’s total well-being. SimpleTherapy’s solutions are:

• SimpleMSK: Their flagship, comprehensive MSK solution, combines tech-guided and evidence-based care with virtual and in-person providers, where members can access a nationwide network of PT, OT, SLP, chiropractic, and acupuncture care, with same/next-day virtual visits and 24/7 triage.
• SimpleBehavioral: Spanning therapy, psychiatry, substance use disorder care, and crisis care routing, SimpleTherapy delivers a complete and integrated mental health benefit administration program focusing on care and compassion at every level specific to the member’s needs.
• SimpleConnect: SimpleTherapy’s newest solution, specific for students and families, is a 24/7, on-demand digital mental health solution that offers emotional well-being support and life-balance resources during evenings, weekends, and school breaks.
• SimpleEAP: Available for employees by phone, web, or app, SimpleEAP provides 24/7/365 access to licensed mental health professionals for immediate, personalized support, including in-the-moment counseling, short-term therapy, work-life services, and manager consultations.
• SimpleWellbing: In a single, integrated platform, SimpleTherapy delivers a holistic wellness experience where members can engage in evidence-based programs for stress resilience and mindfulness, sleep and energy, nutrition and weight management, activity challenges, and preventive MSK micro-sessions.

“We are constantly innovating how we can make health care more accessible for our members in our digital society” said Arpit Khemka, CEO of SimpleTherapy. “This recognition acknowledges that goal and elevates us to keep pushing forward with new technological advancements while keeping our solutions people-focused.”

For more details, read about SimpleTherapy’s recognition here.

About SimpleTherapy

SimpleTherapy is redefining care through innovative, clinically validated solutions for physical, musculoskeletal (MSK), and behavioral health. Our platform blends digital tools, virtual services, and a nationwide network of over 60,000 providers to deliver simple, personalized support. We help organizations of all sizes, including Fortune 50 companies, improve health outcomes, lower costs, and support their workforce in new, meaningful ways. Learn more at simpletherapy.com or reach out to sales@simpletherapy.com.

About The Healthcare Technology Report

The Healthcare Technology Report is a trusted resource for insights on companies transforming healthcare through technological innovation. Its annual Top 50 list highlights organizations demonstrating exceptional leadership, impact, and commitment to advancing healthcare delivery.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1d29d75a-fa9e-4feb-8670-1a0e83c713b9

CONTACT: CONTACT Rebecca Rawl, Director of Marketing
COMPANY SimpleTherapy
PHONE 443-857-8718
EMAIL rebecca.rawl@simpletherapy.com 
WEB simpletherapy.com